Navigating an Increasingly Complex Treatment Paradigm in the Management of Type 2 Diabetes: Optimizing Cardiovascular and Renal Outcomes with SGLT2 Inhibitors

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive of the live session from the 2021 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from July 1, 2021 – August 1, 2022
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
AstraZeneca

Description:
The American Diabetes Association (ADA) estimates that more than 30.3 million people in the United States, or 9.4 percent of the population, have diabetes, and that one in three Americans born in 2019 will develop diabetes sometime during their lifetime. About 90-95% of adults who have diabetes have type 2 diabetes mellitus (DM). According to the Centers for Disease Control (CDC), uncontrolled type 2 DM doubles a person’s risk for death, and on average individuals with type 2 DM lose 10-15 years of life. The management of type 2 DM remains a major challenge as many patients continue to struggle with achieving therapeutic goals, including control of A1C level, blood pressure, cholesterol, and weight. Fortunately, recent advances in treatments in Type 2 Diabetes management have given healthcare professionals the ability to shrink this clinical practice gap. The economic cost of diabetes is staggering. According to the National Diabetes Information Clearinghouse and ADA, the total estimated cost of diabetes is about $174 billion, including $116 billion in direct medical costs and $58 billion in reduced national productivity. Medical costs attributed to diabetes included $27 billion for care to directly treat diabetes, $58 billion to treat the portion of diabetes-related chronic complications that are attributed to diabetes, and $31 billion in excess general medical costs. Moreover, it has been estimated that people with diagnosed diabetes, on average, have medical expenditures that are approximately 2.3 times higher than what expenditures would be in the absence of diabetes. The price tag associated with treatment of type 2 DM increases with disease severity, as more and more dollars are spent managing the significant comorbidities, such as cardiovascular disease, associated with advanced type 2 DM.

Upon completion of this activity, participants will be able to:

  • Assess the pathophysiologic relationships between T2DM and cardiovascular disease (CVD), heart failure (HF), and chronic kidney disease (CKD), including implications for antihyperglycemic treatment

  • Examine the mechanism(s) supporting the therapeutic potential of SGLT2 inhibitors to target cardiorenal endpoints in patients with T2DM

  • Evaluate safety and efficacy results from clinical trials and real-world studies of SGLT2 inhibitors to optimize cardiorenal outcomes in patients with T2DM

  • Compare the designs and results of large-scale cardiovascular and renal outcomes trials with SGLT2 inhibitors for T2DM

  • Collaborate with managed care professionals and clinicians to manage patients with T2DM based on cardiovascular and renal risks, recent guideline recommendations, and other clinical parameters

  • Assess the managed care considerations of SGLT2 inhibitors by exploring where these agents fit into the evolving T2DM management paradigm for optimizing cardiovascular and renal outcomes

     

Faculty: Richard E. Pratley, MD
Samuel E. Crockett Chair in Diabetes Research
Medical Director, AdventHealth Diabetes Institute
Adjunct Professor of Medicine, Johns Hopkins University School of Medicine

Disclosure:

Dr. Pratley serves as a consultant for Merck, Novo Nordisk, Pfizer, Sanofi, Scohia Pharma, and Sun Pharmaceuticals. He serves on the speaker's bureau for Novo Nordisk. He has received grants/research funding from Hanmi Pharmaceutical Company, Janssen, Metavention, Novo Nordisk, Poxel SA, and Sanofi. His presentation has been peer reviewed for any bias. His presentation has been reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no financial relationships with ineligible companies to disclose.
Jeremy Williams has no financial relationships with ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial relationships with ineligible companies to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
AstraZeneca

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue